Common Contracts
2 similar Underwriting Agreement contracts by Amag Pharmaceuticals Inc., Trinity Industries Inc
AMAG PHARMACEUTICALS, INC. Underwriting AgreementUnderwriting Agreement • February 14th, 2014 • Amag Pharmaceuticals Inc. • Pharmaceutical preparations • New York
AMAG Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several Underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representative (the “Representative”), $175,000,000 principal amount of its 2.50% Convertible Senior Notes due 2019 (the “Underwritten Securities”) and, at the option of the Underwriters, up to an additional $25,000,000 principal amount of its 2.50% Convertible Senior Notes due 2019 (the “Option Securities”) if and to the extent that the Underwriters shall have determined to exercise the option to purchase such 2.50% Convertible Senior Notes due 2019 granted to the Underwriters in Section 2 hereof. The Underwritten Securities and the Option Securities are herein referred to as the “Securities”. The Securities will be convertible into cash, shares of common stock of the Company, par value $0.01 per share (the “Common Stock”), or a combination of cash and shares of Common Stock at the Compan
Trinity Industries, Inc. Underwriting AgreementUnderwriting Agreement • June 7th, 2006 • Trinity Industries Inc • Railroad equipment • New York
Trinity Industries, Inc. (the “Company”) proposes, subject to the terms and conditions stated herein, to issue and sell to the several Underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), $450,000,000 principal amount of its 3 7/8% Convertible Subordinated Notes due 2036 (the “Firm Securities”) to be issued pursuant to the provisions of an Indenture dated as of June 1, 2006 (the “Indenture”) between the Company and Wells Fargo Bank, National Association, as Trustee (the “Trustee”) and, at the option of the Underwriters, to cover over-allotments, if any, up to an additional $50,000,000 principal amount of its 3 7/8% Convertible Subordinated Notes due 2036 (the “Option Securities”). The Firm Securities and the Option Securities are hereinafter collectively referred to as the “Securities”. The Securities will be convertible into shares (the “Underlying Securities”) of common stock of the Company, par value $1.00
